COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Features and Outcomes of Patients With Reactive Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03926429
Recruitment Status : Completed
First Posted : April 24, 2019
Last Update Posted : April 24, 2019
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:
The aim of this study is to assess the incidence and the clinical and therapeutic characteristics of reactive arthritis and to compare them with those of a historical cohort. We hypothesised that improved hygiene together with prevention and treatment of sexually transmitted infections may have decreased the incidence of reactive arthritis.

Condition or disease Intervention/treatment
Arthritis Other: Standardised data collection

Layout table for study information
Study Type : Observational
Actual Enrollment : 58 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Bicentre Retrospective Study of Features and Outcomes of Patients With Reactive Arthritis
Actual Study Start Date : February 1, 2013
Actual Primary Completion Date : December 31, 2014
Actual Study Completion Date : December 31, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arthritis

Group/Cohort Intervention/treatment
Patient with reactive arthritis Other: Standardised data collection
The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).

Primary Outcome Measures :
  1. To determine the incidence of reactive arthritis in patients hospitalised in the rheumatology department [ Time Frame: December 2014 ]
    Incidence of reactive arthritis in patients hospitalised in the rheumatology department

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with active reactive arthritis

Inclusion Criteria:

  • reactive arthritis diagnosed in one of the two rheumatology departments from Centre Hospitalier Lyon Sud or Besançon

Exclusion Criteria:

  • presence of other known causes of arthritis, such as other defined spondyloarthritides, septic arthritis, Lyme disease, microcrystalline arthritis or rheumatoid arthritis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03926429

Layout table for location information
CHU de Besançon
Besançon, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for investigator information
Principal Investigator: Fabienne COURY-LUCAS, MD Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon Identifier: NCT03926429    
Other Study ID Numbers: FOPRA
First Posted: April 24, 2019    Key Record Dates
Last Update Posted: April 24, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Reactive
Joint Diseases
Musculoskeletal Diseases
Arthritis, Infectious
Spinal Diseases
Bone Diseases